Tesamorelin

Tesamorelin is a GHRH analogue with a trans-3-hexenoic acid group conjugated to its N-terminus, protecting it against DPP-IV cleavage and extending half-life to approximately 26 minutes (vs ~7 minutes for native GHRH). This preserves full GHRH receptor activity.

Tesamorelin selectively activates pituitary GHRH receptors, producing pulsatile GH release that maintains physiological feedback loops. Research has focused specifically on its ability to reduce visceral adiposity — a metabolic effect of GH axis stimulation.

FDA approval for HIV-related lipodystrophy was based on Phase 3 trials showing 15–18% reduction in visceral adipose tissue. Research in HIV-negative subjects showed similar significant reductions. IGF-1 levels increased 60–70% over treatment periods.

Store lyophilized at -20°C. Reconstituted solution stable 28 days at 2–8°C. Bacteriostatic water recommended.